GLP-1 Receptor Agonists Go Head-to-Head

This short slide show summarizes results of 8 phase III clinical trials, revealing favorable class efficacy and also differences that should be considered before treatment selection.

The class of injectable glucagon-like peptide-1 receptor agonists (GLP-1 RA) has grown over the past decade to include 4 agents approved in the US and the UK, one additional in the UK only, and there are several more molecules in the pipeline.A recent analysis published in Therapeutic Advances in Endocrinology and Metabolism provides a comprehensive comparison of 8 head-to-head clinical trials of these agents that target hyperglycemia in type 2 diabetes. All GLP-1 RAs are effective therapeutic options to reduce A1c. There are differences, however, in the magnitude of this effect, their effect on weight (loss), and in the frequency and severity of adverse events associated with each. The slides above offer an at-a-glance summary of the review.Exenatide (Byetta/Bydureon), approved in 2005/2012Liraglutide (Victoza, Saxenda), approved 2010Lixisenatide (Lyxumia), approved in EU 2013Albiglutide (Tanzeum), approved in 2014Dulaglutide (Trulicity), approved in 2014

References:

Trujillo JM, Nuffer W, Ellis SL DF. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv EndocrinolMetab. 2015;6:19–28. DOI: 10.1177/ 2042018814559725